Iterum Therapeutics PLC (NASDAQ:ITRM) was the recipient of a significant growth in short interest in December. As of December 31st, there was short interest totalling 336,400 shares, a growth of 21.3% from the December 15th total of 277,400 shares. Approximately 5.0% of the company’s stock are short sold. Based on an average trading volume of 278,600 shares, the short-interest ratio is currently 1.2 days.
Iterum Therapeutics stock opened at $4.03 on Wednesday. The company has a 50-day simple moving average of $3.42 and a 200-day simple moving average of $4.89. The firm has a market capitalization of $56.26 million, a P/E ratio of -0.57 and a beta of 2.21. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.99 and a current ratio of 0.99. Iterum Therapeutics has a one year low of $1.68 and a one year high of $9.30.
Iterum Therapeutics (NASDAQ:ITRM) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($2.15) EPS for the quarter, missing the consensus estimate of ($1.61) by ($0.54). As a group, sell-side analysts forecast that Iterum Therapeutics will post -7.19 earnings per share for the current year.
ITRM has been the topic of several recent analyst reports. Royal Bank of Canada cut their price target on shares of Iterum Therapeutics from $14.00 to $10.00 and set an “outperform” rating on the stock in a report on Wednesday, December 11th. Zacks Investment Research upgraded shares of Iterum Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, November 19th. ValuEngine upgraded shares of Iterum Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, October 4th. Svb Leerink reiterated a “market perform” rating and set a $4.00 target price (down previously from $14.00) on shares of Iterum Therapeutics in a research note on Wednesday, December 11th. Finally, Leerink Swann lowered shares of Iterum Therapeutics from an “outperform” rating to a “market perform” rating and set a $4.00 target price for the company. in a research note on Wednesday, December 11th. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Iterum Therapeutics currently has a consensus rating of “Buy” and an average price target of $10.67.
An institutional investor recently raised its position in Iterum Therapeutics stock. Granahan Investment Management Inc. MA raised its position in shares of Iterum Therapeutics PLC (NASDAQ:ITRM) by 4.0% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 242,226 shares of the company’s stock after buying an additional 9,360 shares during the quarter. Granahan Investment Management Inc. MA owned 1.74% of Iterum Therapeutics worth $1,398,000 at the end of the most recent quarter. 42.85% of the stock is currently owned by hedge funds and other institutional investors.
Iterum Therapeutics Company Profile
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of adults in uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.
See Also: Options Trading – What is a Straddle?
Receive News & Ratings for Iterum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iterum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.